| ²é¿´: 1266 | »Ø¸´: 1 | ||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û1´Î£¬×÷Õßµç×ÓÔÆÔö¼Ó½ð±Ò 0.8 ¸ö | ||
[×ÊÔ´]
2011Äê¶ÈNSFC-NIHÉúÎïҽѧºÏ×÷ÊÔµãÏîÄ¿ÉêÇëÖ¸ÄÏ
|
||
|
Ïà¹ØÁìÓòµÄ³æÓÑÃÇ¿ÉÒÔ¹Ø×¢2012ÄêµÄÉêÇëÖ¸ÄÏ£¬ËäȻָÄÏ»¹Î´³ö£¬µ«ÊÇ2011ÄêµÄÖ¸ÄÏÖµµÃ½è¼ø²Î¿¼£¡²»¹ýÒòΪÊÇÊÔµãÏîÄ¿£¬Ò²Ðí»áÓбȽϴóµÄ±ä»¯Ò²Ëµ²»¶¨£¡ ¸ù¾Ý¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðίԱ»á£¨NSFC£©ÓëÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº£¨NIH£©2010Äê10ÔÂÇ©ÊðµÄ¿ÆÑ§ºÏ×÷Á½ⱸÍü¼£¬Îª´Ù½øÁ½¹úÔÚÉúÎïҽѧÁìÓòµÄºÏ×÷£¬Ë«·½ÓÚ2011Ä깲ͬÕ÷¼¯¡¢×ÊÖúºÏ×÷ÊÔµãÏîÄ¿£¬Ö§³ÖÖÐÃÀÁ½¹ú¿ÆÑ§¼ÒÔÚÖ×Áö¡¢¹ýÃôÐÔ¼²²¡¡¢¸ÐȾÐÔ¼²²¡£¨°üÀ¨HIV/°¬×̲¡¼°Æä²¢·¢Ö¢£©¡¢Ò½Ñ§ÃâÒßµÈÁìÓò¿ªÕ¹ºÏ×÷¡£¾ßÌåÏîĿ˵Ã÷ºÍÉêÇëÒªÇóÈçÏ£º ¡¡¡¡Ò»¡¢ÏîĿ˵Ã÷ ¡¡¡¡£¨Ò»£©×ÊÖúÏîÄ¿Êý£º²»³¬¹ý33¸ö¡£ ¡¡¡¡£¨¶þ£©×ÊÖúÇ¿¶ÈÓëÄÚÈÝ£ºÖз½Æ½¾ù30ÍòÔª/ÏÃÀ·½²»³¬¹ý10ÍòÃÀÔª/Ïî¡£±¾ºÏ×÷ÏîĿ˫·½²ÉÓá°Åɳö·½¡±ÔÔò£¬¼´Ë«·½¸ºÔð×ÊÖú±¾¹ú¿ÆÑ§¼ÒµÄÑо¿¾·ÑºÍΪ¿ªÕ¹Ë«±ß½»Á÷ËùÐè³ö·Ã¹ú¼ÊÂ÷Ѽ°¹úÍâÉú»î·Ñ¡£ ¡¡¡¡£¨Èý£©ÏîĿִÐÐÈÕÆÚ£º2012Äê1ÔÂ1ÈÕ¡«2012Äê12ÔÂ31ÈÕ¡£ ¡¡¡¡£¨ËÄ£©×ÊÖúÁìÓò¼°ÉêÇë´úÂ룺ÒÔÏÂÁгöµÄ×ÊÖúÁìÓòºÍ·½ÏòÖ»ÊǾÙÀý˵Ã÷£¬Ë«·½×ÊÖúµÄÁìÓòºÍ·½Ïò²¢²»½öÏÞÓÚ´Ë£¬Ö»ÒªÉêÇëÈ˵ÄÑо¿ÄÚÈÝÓëÖ×Áö¡¢¹ýÃôÐÔ¼²²¡»òҽѧÃâÒߺ͸ÐȾÐÔ¼²²¡£¨°üÀ¨HIV/°¬×̲¡¼°Æä²¢·¢Ö¢£©Ïà¹Ø£¬¾ù¿É°´ÕÕ±¾ÏîÄ¿ÉêÇëÖ¸ÄϵÄÒªÇóÌá½»ÉêÇë¡£ ¡¡¡¡1¡¢Ö×ÁöÁìÓò¡¾ÉêÇë´úÂ룺H16¡¿£º ¡¡¡¡¡ñ ¶ÔÖÐÃÀÁ½¹ú³£¼ûÖ×ÁöµÄ²¡ÀíѧºÍÉúÎïѧÑо¿ÒÔ¼°¶Ôº±¼ûÖ×ÁöµÄºÏ×÷Ñо¿£¨Studies on the pathobiology of cancers in China or the U.S. and studies of rare tumors where there is a benefit to U.S.-China cooperation to identify sufficient numbers of cases for study£© ¡¡¡¡¡ñ Óë¸ÐȾÏà¹ØµÄÖ×Áö£¬°üÀ¨HIVÏà¹Ø¶ñÐÔÖ×Áö£¨Infection-associated cancers, including HIV-associated malignancies£© ¡¡¡¡¡ñ »ù´¡Ö×ÁöÑо¿ ¡¡¡¡1) Ö×Áö»ùÒò×éѧ£¬°üÀ¨±í¹Û»ùÒò×éѧ¡¢×ªÂ¼×éѧ¡¢µ°°×ÖÊ×éѧºÍ´úл×éѧÑо¿£¨Cancer genomics, including epigenomic, transcriptomic, proteomic and metabolomic studies£© ¡¡¡¡2) ϵͳÉúÎïѧºÍ½á¹¹ÉúÎïѧ£¨Systems biology and structural biology£© ¡¡¡¡3) Ö×ÁöÄÉÃ×¼¼Êõ£¨Cancer nanotechnology£© ¡¡¡¡4) Ö×Áöϸ°ûºÍÖ×ÁöÉúÎïѧ£¨Cancer cell and tumor biology£© ¡¡¡¡5) Ö×Áö¸Éϸ°û£¨Cancer stem cells£© ¡¡¡¡6) ΢»·¾³ºÍÖ×Áö×ªÒÆ¡¢Ö×ÁöÃâÒߺÍÃâÒßÖÎÁÆ¡¢Ö×Áö²¡Òòѧ£¨Microenvironment and metastasis, tumor immunology and immunotherapy, and cancer etiology£© ¡¡¡¡7) Ö×ÁöºÍÑ×Ö¢£¨Cancer and inflammation£© ¡¡¡¡¡ñ Ö×ÁöÁ÷Ðв¡ºÍÈËȺÑо¿£¬°üÀ¨´«È¾Ô´¡¢ÓªÑø¡¢»·¾³ºÍÖ°Òµ±©Â¶¶ÔÓÕ·¢Ö×ÁöµÄÓ°Ï죨Cancer epidemiology and population science studies, including investigations of infectious agents, nutrition, energy balance, environmental and occupational exposures and personal susceptibility factors that may affect cancer risk£© ¡¡¡¡¡ñ ͨ¹ýÖÐÒ½Ñо¿£¬1) ´ÓÊÀ½çÎÀÉú×éÖ¯¹æ¶¨µÄ´«Í³Ò½ÁÆÌåϵҩµäÖз¢¾òÐÂÁÆ·¨£¨identify novel therapeutics in the pharmacopeia of traditional medical systems as defined by the World Health Organization£©£»2) Ìá¸ßÏÖÓеıê×¼ÐͺÍÑо¿ÐÍ¿¹°©ÁÆ·¨µÄÖÎÁƱÈÀý£¨improve the therapeutic ratio of standard and investigational anti-cancer therapies£©£»ÒÔ¼°3) Ñо¿Éú»î·½Ê½µÄ¸Ä±ä¶ÔÖ×ÁöÔ¤ºóµÄÓ°Ï죨conduct research on the impact of lifestyle modifications £¨e.g. diet, exercise, mind-body approadches£©on cancer outcome(e.g. response to conventional cancer therapy, surivival)£© ¡¡¡¡2¡¢¹ýÃôÐÔ¼²²¡£¨ÉêÇë´úÂ룺H10£©¡¢¸ÐȾÐÔ¼²²¡£¨ÉêÇë´úÂ룺H19£©ºÍҽѧÃâÒßѧ£¨ÉêÇë´úÂ룺H10£©ÁìÓò£º ¡¡¡¡¡ñ HIV¸ÐȾºÍ°¬×̲¡¼°Æä²¢·¢Ö¢ºÍ²¢Óм²²¡£¨°üÀ¨ºÏ²¢¸ÐȾ¡¢¶ñÐÔÖ×Áö¡¢¿¹Äæ×ªÂ¼²¡¶¾ÖÎÁƺϲ¢Ö¢¡¢½áºË¡¢¸ÎÑס¢´úлÒì³£¡¢ÐÄѪ¹Ü¡¢ÀÏÄêÉñ¾ÈÏÖª¹¦ÄÜÕϰ£©£¨HIV/AIDS and its co-morbidities including , but not limited to, co-infections, AIDS-defining and non-AIDS defining malignancies, and complications associated with long-term HIV disease and antiretroviral therapy (ART), including tuberculosis, hepatitis C and hepatitis B, metabolic disorders, cardiovascular disease, conditions associated with aging, and neurologic and neurocognitive disorders.£© ¡¡¡¡¡ñ Ïø´ºÍ¹ýÃôÐÔ¼²²¡£¬°üÀ¨»·¾³ÎÛȾÎï¡¢¸ÐȾ¼°¹ýÃôÔµÄÓ°Ï죨Asthma and allergic disease, including the role of environmental pollutants, infections and allergens£© ¡¡¡¡¡ñ ҽѧÃâÒßѧ£¨Basic immunology and immunity studies£© ¡¡¡¡¡ñ È«Çò·¶Î§ÄÚ¸÷ÖÖз¢»òÔÙ·¢ÐÔ´«È¾²¡£¬Ö÷ÒªµÄÓÅÏÈÁìÓòÓУº ¡¡¡¡1) È綯ÎïÔ´ÐÔ´«È¾²¡£º¹³¶ËÂÝÐýÌå¡¢²¼Â³ÊϾú¡¢Á¢¿Ë´ÎÊÏÌåµÈ£¨Zoonotic diseases, including leptospirosis, brucellosis, melioidosis, rickettsioses£© ¡¡¡¡2) Âé·ç²¡ºÍ²¼Â·ÀïÀ£Ññ£¨Leprosy and Buruli ulcer£© ¡¡¡¡3) ²¡¶¾Ô´ÐÔ¼²²¡£¬ÌرðÊdz¦µÀ²¡¶¾71£¨Viral pathogens, especially enterovirus 71£© ¡¡¡¡4) ºôÎüµÀ¼²²¡£¬È磺·Î½áºË¡¢Á÷¸Ð¡¢ÄÎɪ¾úºÍÁ´Çò¾úÐÔ·ÎÑ×£¨Respiratory diseases, including tuberculosis, influenza, Neisseria meningitidis, and Streptococcus pneumoniae£© ¡¡¡¡5) ÐÔ´«²¥¼²²¡£¬È磺ϸ¾úÐԺ͵γæÐÔÒõµÀÑ׵ȣ¨Sexually transmitted infections: bacterial vaginosis,Haemophilus ducreyi and trichomoniasis£© ¡¡¡¡6) ¼ÄÉú³æÐÔ¼²²¡µÈ £¨Parasitic diseases and vectors£© ¡¡¡¡7) Èѳ½¸¾Å®µÄÎìÐ͸ÎÑ×£¨Hepatitis E in pregnant women£© ¡¡¡¡8) ³¦¶¾ÐԴ󳦸˾ú¡¢Ö¾ºØÊϾú¡¢ººÌ¹²¡¶¾¡¢µÇ¸ïÈÈ¡¢ÁѹÈÈÈ¡¢ÈÕ±¾ÄÔÑס¢Î÷ÄáÂÞ²¡¶¾µÈ¡££¨Enterotoxigenic Escherichia coli, Shigella, hantaviruses, dengue, Rift Valley fever, Japanese encephalitis virus and West Nile virus£© ¡¡¡¡Öз½ÉêÇëÈËÐëÑ¡ÔñÉÏÊöÁгöµÄÉêÇë´úÂ루H16»òH10»òH19£©ÌîдÖÐÎÄÉêÇëÊ飬¶ÔÓÚδ°´ÒªÇóÌîд´ËÖ¸¶¨ÉêÇë´úÂëµÄÉêÇëÊ飬½«²»ÓèÊÜÀí¡£ ¡¡¡¡¶þ¡¢ÉêÇëÒªÇó ¡¡¡¡£¨Ò»£©Öз½ÉêÇëÈËÐë¾ßÓи߼¶×¨Òµ¼¼ÊõÖ°Îñ£¨Ö°³Æ£©£¬ÐëÊÇÕýÔڳе£»ò³Ðµ£¹ý3ÄêÆÚÒÔÉϹú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿µÄ¸ºÔðÈË£» ¡¡¡¡£¨¶þ£©ÖÐÃÀË«·½¿ÆÑ§¼ÒÖ®¼äÓ¦ÓнϺõĺÏ×÷»ù´¡ºÍDZÁ¦£» ¡¡¡¡£¨Èý£©NIHµÄ×ÊÖú¶ÔÏó°üÀ¨ÆäÔºÄÚÑо¿ÈËÔ±ºÍÔºÍâÑо¿ÈËÔ±£¬ÃÀ·½ºÏ×÷ÕßÐë°´ÕÕNIH·Ö±ð·¢²¼µÄÏîÄ¿Õ÷¼¯Í¨ÖªÖеľßÌåÒªÇó½øÐÐÉ걨¡£Öз½ÉêÇëÈ˺ÍÃÀ·½ºÏ×÷ÕßÒª³ä·Ö¹µÍ¨ÐÉÌ£¬ÔÚ´Ë»ù´¡ÉÏÌîдNIHÒªÇóµÄÓ¢ÎÄÉêÇë²ÄÁÏ¡£¸ÃÓ¢ÎÄÉêÇë²ÄÁϽ«×÷Ϊ˫·½ÆÀÉóµÄÒÀ¾Ý£¬ÖÐÃÀË«·½×ÊÖú»ú¹¹¼°Ë«·½¿ÆÑ§¼ÒÐëÑϸñ×ñÊØË«·½Ïà¹Ø±£Ãܹ涨¡£ ¡¡¡¡£¨ËÄ£©Ë«·½ºÏ×÷ÕßÓ¦°´ÕÕÒªÇó·Ö±ðÏòÎÒίºÍNIHÌá½»ÉêÇ룬µ¥·½ÉêÇëÊÓΪÎÞЧ¡£ ¡¡¡¡Èý¡¢ÏÞÏî¹æ¶¨ ¡¡¡¡£¨Ò»£©´ËÏîĿΪÖÐÃÀË«·½ÊÔµãÏîÄ¿£¬Öз½ÉêÇëÈ˲»²ÎÓëÏÞÏî²éÖØ¡£ ¡¡¡¡£¨¶þ£©Öз½ÉêÇëÈË£¨²»º¬²ÎÓëÕߣ©Í¬ÄêÖ»ÄÜÉêÇë1Ïî±¾ÏîÄ¿¡£ ¡¡¡¡ËÄ¡¢É걨˵Ã÷ ¡¡¡¡£¨Ò»£©Öз½ÉêÇëÈËÐëµÇ¼ISIS¿ÆÑ§»ù½ðÍøÂçϵͳ£¨http://isis.nsfc.gov.cn£©£¬ÔÚÏßÌ¡¶¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¹ú¼Ê£¨µØÇø£©ºÏ×÷Óë½»Á÷ÏîÄ¿ÉêÇëÊé¡·(ÒÔϼò³Æ¡°ÖÐÎÄÉêÇëÊ顱)¡£¾ßÌå²½ÖèÊÇ£ºÑ¡Ôñ¡°ÏîÄ¿¸ºÔðÈË¡±Óû§×éµÇ¼ϵͳ£¬½øÈëºóµã»÷¡°¹ú¼ÊºÏ×÷ÏîÄ¿ÉêÇ롱һÀ¸Öеġ°ÉêÇë¹ú¼ÊºÏ×÷ÀàÏîÄ¿¡±£¬ÔÙµã»÷¡°ÌîдÉêÇëÊ顱°´Å¥£¬ÔÚÏîÄ¿ÀàÐÍÖÐÑ¡Ôñ¡°ºÏ×÷Ñо¿¡±£¬µã»÷Õ¹¿ª×ÓÀà±ðºó£¬Ñ¡ÔñÏîÄ¿Ãû³Æ¡°NSFC-NIHÏîÄ¿£¨ÖÐÃÀ£©¡±£¬Çë°´ÕÕϵͳÌáʾÌîÈëÒ»¸öÉêÇëÈËÔø¾Ö÷³Ö¹ý»òÕýÔÚÖ÷³ÖµÄÈýÄêÆÚ£¨º¬£©ÒÔÉϹú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿±àºÅ£¬Í¨¹ýϵͳÉóºËÖ®ºó£¬¼´¿É½øÈëÉêÇëÊéÌîд½çÃæ£¬ÔÚÏßÌîд²¢Ìá½»ÉêÇëÊé¡£ ¡¡¡¡£¨¶þ£©ÖÐÎÄÉêÇëÊéµÄÄÚÈÝÓ¦ÓëÓ¢ÎÄÉêÇë²ÄÁÏÄÚÈÝÒ»Ö¡£Áí£¬ÏîĿӢÎÄÃû³ÆÐëÓëÃÀ·½ºÏ×÷ÕßÌá½»µÄÓ¢ÎÄÏîÄ¿Ãû³ÆÍêȫһÖ¡£ ¡¡¡¡£¨Èý£©ÉêÇ븽¼þ²ÄÁÏ£º ¡¡¡¡1¡¢ÉêÇëÈËÐëÁíҳרÃÅ˵Ã÷ÖÐÃÀË«·½¸÷×ÔµÄÔ¤Ë㣬²¢ÒÔ¸½¼þµÄÐÎʽÔÚISISϵͳÖÐÉÏ´«¡£ ¡¡¡¡2¡¢Öз½ÉêÇëÈ˳ýÁËÔÚÏßÌîдÌá½»ÖÐÎÄÉêÇëÊéÒÔÍ⣬»¹ÐëÌá½»ÃÀ·½ºÏ×÷ÕßÏòNIHÌá½»µÄÈ«Ì×Ó¢ÎÄÉêÇë²ÄÁϵĸ±±¾¡£ÎÞ´ËÓ¢ÎÄÉêÇë²ÄÁϸ±±¾µÄ£¬ÊÓΪÎÞЧÉêÇë¡£ ¡¡¡¡3¡¢ÉêÇëÈËÐëÒÔ¸½¼þµÄÐÎʽ½«Ë«·½ÉêÇëÈ˵ÄÓ¢ÎÄѧÊõ¼òÀú¡¢½üÆÚ¹«¿ª·¢±íµÄ´ú±íÐÔÎÄÕÂĿ¼£¨Ë«·½¸÷5ƪ£©¼°ÃÀ·½ºÏ×÷ÕßÌṩµÄºÏ×÷È·ÈϺ¯Ò»²¢ÔÚISISϵͳÖÐÌá½»¡£Ë«·½ºÏ×÷ÕßÐëÔÚºÏ×÷È·ÈϺ¯ÖгÂÊöË«·½µÄºÏ×÷»ù´¡¡¢ºÏ×÷Ñо¿»¥²¹ÐÔ¡¢Ô¤ÆÚºÏ×÷³É¹û¼°ÆäÓ°ÏìµÈ·½ÃæµÄÄÚÈÝ¡£ ¡¡¡¡£¨ËÄ£©ÖÐÎÄÉêÇëÊéÌîдÍê³ÉÈ·ÈÏÎÞÎóºó£¬µã»÷Ìá½»£¬²¢½«ÏµÍ³×Ô¶¯Éú³ÉµÄPDFÎļþ´òÓ¡Ò»·Ý¡£µç×Ó°æÉêÇëÊéÐè¾ÒÀÍе¥Î»È·ÈÏÌá½»ÖÁÎÒί£»Ö½ÖÊÉêÇëÊé¾ÒÀÍе¥Î»Ç©×Ö¸ÇÕºó£¬Á¬Í¬±¾²¿·ÖµÚ£¨Èý£©ÌõËùÁÐÉêÇ븽¼þ²ÄÁÏÒ»²¢±¨ËÍ»ù½ðί¹ú¼ÊºÏ×÷¾ÖÃÀ´ó´¦ (µØÖ·¼ûºó)¡£ ¡¡¡¡Îå¡¢Öз½ÏîÄ¿ÉêÇë½ØÖ¹Ê±¼ä£º2011Äê4ÔÂ18ÈÕ£¨Ö½ÖÊÉêÇë²ÄÁÏÒÔÓÊ´ÁΪ׼£©¡£ ¡¡¡¡ÃÀ·½ÏîÄ¿ÉêÇë½ØÖ¹Ê±¼äÒÔÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº·¢²¼µÄÏîÄ¿ÉêÇëÖ¸ÄϵÄÒªÇóΪ׼£¬Ë«·½ÉêÇëÈËӦȷ±£¸÷×ÔÔÚÏîÄ¿ÉêÇë½ØÖ¹ÈÕÆÚǰÌá½»ÉêÇë¡£ |
» ²ÂÄãϲ»¶
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ5È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
NSFC 2012Äê¶È¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîĿָÄÏÒÑÔÚÍøÉϹ«²¼
ÒѾÓÐ6È˻ظ´
¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðίԱ»á¹ØÓÚ·¢²¼¡°Ê¯ÓÍ»¯¹¤ÁªºÏ»ù½ð¡±2011Äê¶ÈÏîĿָÄϵÄͨ¸æ
ÒѾÓÐ8È˻ظ´
ÒÀÍÐÏÖÓÐNSFC»ù½ð£¬ÈçºÎÉêÇë»ù½ðί¹ú¼ÊºÏ×÷Ñо¿£¿
ÒѾÓÐ9È˻ظ´
Ìîд2011Äê¶ÈnsfcÏîÄ¿×ÊÖú¼Æ»®Êéʱ¾·ÑÔ¤ËãµÄÎÊÌâ
ÒѾÓÐ6È˻ظ´
2012Äê973ÏîÄ¿ÉúÎïҽѧÏà¹Ø±êÊé10·Ý
ÒѾÓÐ727È˻ظ´
973¼Æ»®2011ÄêÏîÄ¿Çåµ¥£¨ÉúÎïÀࣩ
ÒѾÓÐ11È˻ظ´
2012Äê¶ÈNSFC-JSPSºÏ×÷ÏîĿָÄÏ
ÒѾÓÐ5È˻ظ´
¹ØÓÚ·¢²¼¹ú¼ÒÖØµã»ù´¡Ñо¿·¢Õ¹¼Æ»®2011ÄêÏîÄ¿É걨ָÄÏ
ÒѾÓÐ7È˻ظ´
¡¾·ÖÏí¡¿2011ÄêÈ«Çò¸÷¹ú×ÊÖúÉúÎïҽѧ¾·ÑÕ¹Íû£ºÎ÷·½²»ÁÁ¶«·½ÁÁ
ÒѾÓÐ11È˻ظ´
»ÆÍÁ¸ßÔÍÁÈÀÇÖÊ´Ó뺵µØÅ©Òµ¹ú¼ÒÖØµãʵÑéÊÒ2011Äê¶ÈʵÑéÊÒ¿ª·Å»ù½ð¿ÎÌâÖ¸ÄÏ
ÒѾÓÐ3È˻ظ´
Çó¡¾ÖÐÃÀNSFC-NSF²ÄÁÏÁìÓòºÏ×÷Ñо¿ÏîÄ¿¡¿ÉêÇë¾Ñé
ÒѾÓÐ80È˻ظ´
¼òµ¥»Ø¸´
tia200212012Â¥
2011-06-26 23:46
»Ø¸´
ÎåÐÇºÃÆÀ














»Ø¸´´ËÂ¥
